



DFW/41  
1614

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT**

Docket Number:  
**10793/46**

Application Number  
**10/029,988**

Filing date  
**December 31, 2001**

Examiner

Art Unit  
**1614**

Invention Title  
**MULTIMERS-ISOLATED MOLECULES  
COMPRISING EPITOPES CONTAINING  
SULFATED MOIETIES, ANTIBODIES TO SUCH  
EPITOPES, AND USES THEREOF**


Inventor(s)  
**A. LEVANON et al.**

Address to:

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the  
United States Postal Service with sufficient postage as first class mail in an  
envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria,  
VA 22313-1450 on: June 3, 2004


By:

  
Kathryn M. Lumb (Reg. No. 46,885)

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicant hereby brings the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. The filing of this Information Disclosure Statement and the attached PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
3. A copy of each patent, publication or other information listed on the modified PTO form 1449 are enclosed.
4. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge or credit any over payment to Deposit Account No. 11-0600. A duplicate copy of this communication is enclosed for charging purposes.

Dated: June 3, 2004

By:

  
Kathryn M. Lumb (Reg. No. 46,885)

KENYON & KENYON  
One Broadway  
New York, N.Y. 10004  
(212) 425-7200 (Telephone)  
(212) 425-5288 (Facsimile)  
CUSTOMER NO. 26646



U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT**

Docket Number:  
**10793/46**

Application Number  
**10/029,988**

Filing date  
**December 31, 2001**

Examiner

Art Unit  
**1614**

Invention Title

**MULTIMERS-ISOLATED MOLECULES  
COMPRISING EPITOPES CONTAINING  
SULFATED MOIETIES, ANTIBODIES TO SUCH  
EPITOPES, AND USES THEREOF**

Inventor(s)


**A. LEVANON et al.**

Address to:

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the  
United States Postal Service with sufficient postage as first class mail in an  
envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria,  
VA 22313-1450 on: June 3, 2004


By:

  
Kathryn M. Lumb (Reg. No. 46,885)

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicant hereby brings the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. The filing of this Information Disclosure Statement and the attached PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
3. A copy of each patent, publication or other information listed on the modified PTO form 1449 are enclosed.
4. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge or credit any over payment to Deposit Account No. 11-0600. A duplicate copy of this communication is enclosed for charging purposes.

Dated: June 3, 2004

By:

  
Kathryn M. Lumb (Reg. No. 46,885)

KENYON & KENYON  
One Broadway  
New York, N.Y. 10004  
(212) 425-7200 (Telephone)  
(212) 425-5288 (Facsimile)  
CUSTOMER NO. 26646



**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT BY  
APPLICANT PTO-1449**

ATTY. DOCKET NO.  
**10793/46**

SERIAL NO.  
**10/029,988**

APPLICANT  
**A. LEVANON et al.**

FILING DATE  
**December 31, 2001**

GROUP  
**1614**

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*
	5,716,836	February 10, 1998	Suiko			
	5,827,817	October 27, 1998	Larsen et al.			
	6,124,267	September 26, 2000	McEver et al.			
	6,548,636 B2	April 15, 2003	Dragie et al.			
	6,593,459 B1	July 15, 2003	Cummings et al.			

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 93/11778	June 24, 1993					

**OTHER DOCUMENTS**

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Hagay, Y., et al., "Function-modulating human monoclonal antibodies against platelet-membrane receptors isolated from a phage-display library" Journal of Thrombosis and Haemostasis, Vol. 1, pp. 1829-1836

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	